2. Stem Cell/Wnt Apoptosis Autophagy
  3. YAP Apoptosis Autophagy
  4. Verteporfin

Verteporfin  (Synonyms: 维替泊芬; CL 318952)

目录号: HY-B0146 纯度: 99.26%
COA 产品使用指南

摩尔计算器

Verteporfin (CL 318952) 是一种用于光动力疗法的光敏剂，用于消除与年龄相关的黄斑变性等疾病相关的眼内异常血管。 Verteporfin 是一种 YAP 抑制剂，可破坏 YAP-TEAD 相互作用。Verteporfin 可以诱导细胞凋亡 (apoptosis)。Verteporfin 是一种自噬 (autophagy) 抑制剂，通过抑制自噬小体形成，在早期阻断自噬。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Verteporfin Chemical Structure

Verteporfin Chemical Structure

CAS No. : 129497-78-5

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥1297
In-stock
5 mg ￥990
In-stock
10 mg ￥1520
In-stock
50 mg ￥5800
In-stock
100 mg 现货 询价
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Verteporfin:

Verteporfin 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 168 篇科研文献

WB
IHC
IF
RT-PCR
Proliferation Assay
Cell Viability Assay

    Verteporfin purchased from MCE. Usage Cited in: J Transl Med. 2023 Apr 1;21(1):238.  [Abstract]

    Verteporfin (13.9 µM; 10 µg/mL; 24 h) decreases the expression of YAP and CDX2 in NSCCs.

    Verteporfin purchased from MCE. Usage Cited in: Reprod Sci. 2023 Mar 20.  [Abstract]

    Verteporfin (0.5, 1, 2 µM) decreases the expression of anti-apoptotic marker B cell leukemia 2 (Bcl2), while increases the expression of pro-apoptotic protein Bcl2-associated X protein (Bax) in Ishikawa cells, in a concentration-dependent manner.

    Verteporfin purchased from MCE. Usage Cited in: Reprod Sci. 2023 Mar 20.  [Abstract]

    Verteporfin (0-5 µM; 24 h) decreases the viability of Ishikawa cells in a concentration-dependent manner (IC50 = 1.345 µM).

    Verteporfin purchased from MCE. Usage Cited in: Cell Res. 2022 Jun;32(6):543-554.  [Abstract]

    Survival of mice with striatal GL261 tumor injection with or without RT, saline plus laser treatment, or Verteporfin (Visudyne; 2 mg/mL; 5 μL was injected into the cisterna magna; 15 min) plus laser treatment.

    Verteporfin purchased from MCE. Usage Cited in: Nat Neurosci. 2022 Jul;25(7):849-864.  [Abstract]

    Verteporfin (1 µM)-treated animals exposed to 640 nm in the head exhibits less mrc1a+ cells in the brain compared to non-photoactivated control animals.

    Verteporfin purchased from MCE. Usage Cited in: Nat Commun. 2022 Oct 5;13(1):5871.  [Abstract]

    Mice are injected with either Verteporfin (VP; 100 mg/kg) or vehicle (corn oil) from the postnatal 7 days at 3-day intervals for 14 days. The immunohistochemical assay shows that the expression of TFRC and COX2 is higher in Bnc1tr/tr control mouse ovaries than in Bnc1+/+ control mouse ovaries. Intriguingly, VP treatment partially rescues TFRC and COX2 expression in Bnc1tr/tr mouse ovaries.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 µM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    Compared to cell viability in the vehicle control group, Verteporfin (VP; 100 µM) markedly impairs cell viability assayed by JC-1 staining and CCK-8.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    The expression levels of Hippo-YAP signaling downstream regenerative genes (Ctgf, Ankrd1 and Cyr61) are effectively inhibited by Verteporfin (VP; 100 µM) compared to their expression in the blank control group.

    Verteporfin purchased from MCE. Usage Cited in: Hepatology. 2021 Oct;74(4):2133-2153.  [Abstract]

    The protective effects of TNIP3 against cell inflammation and cell death were largely abolished by Verteporfin (VP; 100 µM) administration.

    Verteporfin purchased from MCE. Usage Cited in: Cell Res. 2020 Mar;30(3):229-243.  [Abstract]

    The representative images of dCLNs and sCLNs 2 weeks after striatal injection of GL261 or B16 cells into mice treated with Vehicle + Laser or =Verteporfin (Visudyne; 2 mg/mL; 5 μL was injected into the cisterna magna; 15 min) + Laser.

    Verteporfin purchased from MCE. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]

    Verteporfin displays a complete suppression of viral CPE at 0.31 µM. Viral N protein expression in infected Vero E6 cells was assessed by immunofluorescence.

    Verteporfin purchased from MCE. Usage Cited in: Sci Bull. 2021 May 15;66(9):925-936.  [Abstract]

    Protoporphyrin IX and Verteporfin effectively prevent SARS-CoV-2 infection in the mouse model expressing human ACE2. Much fewer cells expressed viral N protein in the Protoporphyrin IX and Verteporfin (20 µM) groups compared to the DMSO group.

    Verteporfin purchased from MCE. Usage Cited in: Cancer Cell. 2019 Sep 16;36(3):302-318.e7.  [Abstract]

    Combined treatment of GFAP-Ptch tumor cells with Verteporfin (VP; 24 hours) and CD532 additively decreases proliferation of ZIC1+ tumor cells relative to individual treatments.

    Verteporfin purchased from MCE. Usage Cited in: Mol Cell. 2019 Jan 3;73(1):7-21.e7.  [Abstract]

    Control low metastatic MDA-MB-231 cells or cells overexpressing OTUB2-WT, pretreated with or without Verteporfin (VP, 10 µM) are intracardially injected into nude mice.

    Verteporfin purchased from MCE. Usage Cited in: Mol Immunol. 2019 Mar;107:29-40.  [Abstract]

    Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.

    Verteporfin purchased from MCE. Usage Cited in: Mol Immunol. 2019 Mar;107:29-40.  [Abstract]

    Col1a1 and α-SMA protein levels are analyzed in cells treated with VP.

    Verteporfin purchased from MCE. Usage Cited in: Front Cell Neurosci. 2018 Dec 11;12:489.  [Abstract]

    OECs are treated with vehicle (0.1% DMSO), Y27632 (10 μM) or verteporfin (5 μM) for 24 h and performed WB analysis.

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献

    生物活性

    Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation[3].

    IC50 & Target

    IC50: YAP-TEAD interaction
    体外研究
    (In Vitro)

    Verteporfin 是通过 PDX 细胞筛选特别选择的。PhLO、PhLH 和 PhLK 引起 50% 生长抑制 (GI50) 的浓度分别为 228 nM、395 nM 和 538 nM，而 GI50 ALL-1、TCC-Y/sr 和 NPhA1 分别为 3.93 μM、2.11 μM 和 5.61 μM。GSH 显著降低了 3 个 PDX 细胞中的 2 个对 Verteporfin 的敏感性。Verteporfin 降低 PDX 细胞中的线粒体膜电位[1]。Verteporfin 通过抑制 YAP 表达降低 HCT-8/T 细胞的 PTX 耐药性，与 Verteporfin 联合处理和 NSC 125973 显示出抑制 YAP 和对 HCT-8/T 的细胞毒性的协同作用[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Verteporfin 相关抗体:
    体内研究
    (In Vivo)

    Verteporfin (10 mg/kg，c.s.c.) 和 BMS-354825 显著降低了白血病细胞比例，联合处理进一步降低了脾脏中白血病细胞的数量[1]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    718.79

    Formula

    C41H42N4O8
    CAS 号
    性状

    固体

    颜色

    Brown to black

    中文名称

    维替泊芬
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    溶解性数据
    细胞实验： 

    DMSO 中的溶解度 : 50 mg/mL (69.56 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

    DMF 中的溶解度 : 10 mg/mL (13.91 mM; 超声助溶 (<60°C))

    配制储备液
    浓度 溶剂体积 质量 1 mg 5 mg 10 mg
    1 mM 1.3912 mL 6.9561 mL 13.9123 mL
    5 mM 0.2782 mL 1.3912 mL 2.7825 mL
    查看完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    • 摩尔计算器

    • 稀释计算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量
    =
    浓度
    ×
    体积
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start)

    C1

    ×
    体积 (start)

    V1

    =
    浓度 (final)

    C2

    ×
    体积 (final)

    V2

    动物实验：

    请根据您的 实验动物和给药方式 选择适当的溶解方案。

    以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
    ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
    以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

    • 方案 一

      请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 5 mg/mL (6.96 mM); 澄清溶液

      此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

      生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
    • 方案 二

      请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 5 mg/mL (6.96 mM); 澄清溶液

      此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。

      以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

      20% SBE-β-CD in Saline 的配制（4°C，储存一周）：2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。

    以下溶解方案，请直接配制工作液。建议现用现配，在短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比； 如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。

    • 方案 一

      请依序添加每种溶剂： 50% PEG300    50% Saline

      Solubility: 1 mg/mL (1.39 mM); 悬浊液; 超声助溶

    • 方案 二

      请依序添加每种溶剂： 15% Cremophor EL    85% Saline

      Solubility: 10 mg/mL (13.91 mM); 悬浊液; 超声助溶

    动物溶解方案计算器
    请输入动物实验的基本信息：

    给药剂量

    mg/kg

    动物的平均体重

    g

    每只动物的给药体积

    μL

    动物数量

    只
    由于实验过程有损耗，建议您多配一只动物的量
    请输入您的动物体内配方组成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
    方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
    计算结果
    工作液所需浓度 : mg/mL
    储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

    您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
    动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
    连续给药周期超过半月以上，请谨慎选择该方案。
    请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
    纯度 & 产品资料

    纯度: 99.58%

    COA (296 KB) HNMR (213 KB) RP-HPLC (208 KB)

    产品使用指南 (1538 KB)
    参考文献
    Cell Assay
    [1]

    PDX cells co-cultured with S17 cells are treated with 16 combinations of verteporfin (60 nM, 120 nM, 180 nM, and 240 nM) and BMS-354825 (12 nM, 24 nM, 36 nM, and 48 nM). The viabilities of cells treated with each combination are measured after 48 h using FACS Aria flow cytometer. In order to estimate drug interaction between verteporfin and BMS-354825, a normalized isobologram and fraction affectedcombination index (CI) plot are made using CompuSyn software. CI values greater than 1.0 indicated antagonistic effects, equal to 1.0 additive effects, and below 1.0 synergistic effects.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Mice: PhLO cells (1.0×107/mouse) are injected intravenously into 6-week-old male NOG mice, which are then treated with vehicle, verteporfin (140 mg/kg/day), BMS-354825 (20 mg/kg/day), and a combination of these drugs from days 22 to 28. Verteporfin is administered by continuous subcutaneous infusion (c.s.c.) using Alzet osmotic pumps. An intraperitoneal injection (i.p.) is performed for BMS-354825. All mice are sacrificed on day 28 and the chimerism of leukemia cells is investigated by flow cytometer using an anti-human CD19 antibody and antimouse CD45 antibody. Blood concentrations of verteporfin are calculated by LCMS-2020.

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    参考文献

    Verteporfin 相关分类

    完整储备液配制表

    * 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
    储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

    可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
    DMF / DMSO 1 mM 1.3912 mL 6.9561 mL 13.9123 mL 34.7807 mL
    5 mM 0.2782 mL 1.3912 mL 2.7825 mL 6.9561 mL
    10 mM 0.1391 mL 0.6956 mL 1.3912 mL 3.4781 mL
    DMSO 15 mM 0.0927 mL 0.4637 mL 0.9275 mL 2.3187 mL
    20 mM 0.0696 mL 0.3478 mL 0.6956 mL 1.7390 mL
    25 mM 0.0556 mL 0.2782 mL 0.5565 mL 1.3912 mL
    30 mM 0.0464 mL 0.2319 mL 0.4637 mL 1.1594 mL
    40 mM 0.0348 mL 0.1739 mL 0.3478 mL 0.8695 mL
    50 mM 0.0278 mL 0.1391 mL 0.2782 mL 0.6956 mL
    60 mM 0.0232 mL 0.1159 mL 0.2319 mL 0.5797 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Verteporfin129497-78-5CL 318952维替泊芬CL318952CL-318952YAPApoptosisAutophagyYes-associated proteinInhibitorinhibitorinhibit

    您最近查看的产品:

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * 需求量：

    * 客户姓名：

    		 

    * Email：

    * 电话：

    		 

    * 公司或机构名称：

       留言给我们：

    Bulk Inquiry

    Inquiry Information

    产品名称：
    Verteporfin
    目录号：
    HY-B0146
    需求量：

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

       产品名称：

    		  

    * Lot #：

    * 客户姓名：

    		 

    * Email：

       电话：

    		 

    * 部门：

    * 公司或机构名称：

    		 

       留言给我们：

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.

    嗨！很高兴为您提供帮助！

    尊敬的 MCE 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z